The Food and Drug Administration today published additional information about the Coronavirus Treatment Acceleration Program (CTAP), which seeks to quickly move new COVID-19 treatments to patients, while at the same time finding out whether they are helpful or harmful.
According to an article today by Commissioner Stephen M. Hahn, M.D., and other FDA leaders, 72 clinical trials are being overseen by the agency. The summary highlights several of the therapies currently being tested including antiviral drugs, efforts to suppress the immune system’s overreaction to SARS-CoV-2 and the delivery of antibodies through blood plasma. The full article can be found here.
‹ More News